ADM's Biofuel Windfall Is Real. The Market Is Still Waiting for the Bill.

ADM's Biofuel Windfall Is Real. The Market Is Still Waiting for the Bill.

ADM's third-quarter report is a study in dissonance. The company earned $1.77 in adjusted EPS, grew total segment operating profit 64% to $1.4 billion, and raised full-year guidance for the third time this year. It also resumed buybacks, repurchasing roughly $360 million of stock, and kept net leverage at 1.5x. Yet the shares are down 8.2% over the last 90 trading days and nearly 20% below their September 17 peak. The earnings momentum and the stock price are telling different stories.

The obvious explanation is that investors are debating the durability of a policy-driven margin cycle. The quarter's profit engine was the North American biofuels complex: crush operating profit of $311 million, up roughly $300 million year over year; Refined Products and Other at $218 million, up 82%; and Carbohydrate Solutions at $470 million, up 40%. Management credited the finalized RVO policy and elevated global energy prices for a constructive biofuels environment. Juan Luciano was explicit about the guidance raise: “we are again raising our full year 2026 adjusted EPS guidance. We now expect a range of $5.50 to $5.80 for adjusted EPS, an increase from our prior range of $5.15 to $5.60.” — Juan Luciano, Chair of the Board and Chief Executive Officer · 2026-11-03 Sell-side sentiment was correspondingly effusive.

Third guidance raise in 1 year, beat, higher buybacks and lower CapEx. So this is one of those absolutely flawless quarter.

But the 45Z benefit has been a moving target all year, and that is both the strength and the vulnerability of the story. In February, management sized the 2026 benefit at about $100 million. By May, it was $150 million. In August, it moved to $250 million. Now it is approximately $350 million. The upward revisions reflect genuine operational progress — better carbon-intensity scores, higher ethanol yields, more carbon sequestration — but they also reflect policy pricing and a favorable margin environment. When a benefit keeps getting marked up, investors naturally ask where the ceiling is. The May call captured the pattern: “I think we mentioned last time it was going to be 100 million. Now we're saying it's 150 million.” — Juan Luciano, Chair of the Board and Chief Executive Officer · 2026-05-05 Three months later, the number had nearly tripled again.

The Peak-Cycle Question

The more important tension is whether this is a new earnings base or a cyclical high. Analyst Andrew Strelzik pressed exactly that point, noting that board crush margins have come off their highs and some investors believe the crush cycle is over. Luciano did not dismiss the concern outright: “maybe crush margin peaking in Q3 or they were very high in Q3. We are not seeing a collapse or any of these.” — Juan Luciano, Chair of the Board and Chief Executive Officer · 2026-11-03 That is a carefully worded answer. It says the current level is strong, but it does not say it is rising.

The 2027 framing reinforces the caution. Management described next year as a continuation rather than an acceleration: “We look at '27 with optimism. We see a constructive market structure that actually looks substantially similar to 2026.” — Juan Luciano, Chair of the Board and Chief Executive Officer · 2026-11-03 For a company that just grew segment operating profit 64%, "similar" is a meaningful hedge. It implies the easy year-over-year comparisons are behind it, and that the market should underwrite a plateau, not a new leg up. In a commodity processor, a plateau after a policy-driven spike is precisely what investors fear.

Capital Returns Are the Cleaner Signal

The balance-sheet story is less ambiguous. ADM ended September with net leverage at 1.5x, paid its 379th consecutive quarterly dividend, and bought back stock for the first time in several quarters. Monish Patolawala put the shift plainly: “We also resumed opportunistic share repurchases, buying back approximately $360 million of shares.” — Monish Patolawala, Executive Vice President and Chief Financial Officer · 2026-11-03 That is a real change from May, when Luciano would only say buybacks were plausible: “it is plausible that as our cash flows improve and our balanced capital allocation remains the same way, that potentially, we could do buybacks into the future.” — Juan Luciano, Chair of the Board and Chief Executive Officer · 2026-05-05 The company has moved from talking about capacity to deploying it.

The last filed quarter — Q2, before this report — shows why the market may still hesitate. Operating income was $1.1 billion, up 290% year over year, and net income was $912 million, up 316%. Operating income has recovered violently, yet the valuation has compressed: price to operating income is 17.6x, down from a 27.2x peak in the first quarter of 2026. The market is not paying up for the earnings; it is discounting them. Free cash flow also remains lumpy, and the balance sheet still carries a net debt position: effective net cash was -$2.1 billion in the last filed quarter, though that is an improvement from a year earlier.

The Growth Story Is Still in the Laboratory

With the commodity cycle under scrutiny, management is trying to widen the narrative. New COO Jeff Rowe used his first call to emphasize world-class manufacturing, automation, and AI-enabled decision-making. Luciano devoted a significant block to precision fermentation, describing egg-white alternatives, lamb proteins for pet food, and a whey alternative, all leveraging ADM's existing fermentation assets and dextrose supply. The strategic logic is sound: use sunk-capital assets and customer relationships rather than greenfield plants.

But the timeline is long. “Over the next 2 or 3 years, it will become profitable. And then probably between year 5 and year 10, it will become meaningful, hopefully, for ADM.” — Juan Luciano, Chair of the Board and Chief Executive Officer · 2026-11-03 That is not a 2027 earnings driver. Nor is the voluntary carbon removal initiative at Columbus, which can capture more than 800,000 tons per year of biogenic CO2 but has no quantified 2027 benefit yet. These are options, not cash flows.

Nutrition remains the soft spot. Revenue fell 4%, Human Nutrition operating profit slipped 3%, and management cited unplanned downtime at a plant it declined to identify, along with inflation and softness in biotics. Animal Nutrition grew 21% on portfolio actions and operational improvements, but the segment is not yet a smooth growth engine. The "momentum in Nutrition" language from prior quarters is now more selective.

The political risk is equally visible. Asked about the midterms and the durability of the biofuel framework beyond 2027, Luciano leaned on experience: “I don't expect a fundamental shift.” — Juan Luciano, Chair of the Board and Chief Executive Officer · 2026-11-03 That may prove right — the RVO and 45Z have already survived multiple administrations — but it is an assumption, not a contract. If the policy backdrop changes, the earnings base changes with it.

The third raise is real, and the buyback is a tangible return of capital. But the stock's drawdown says investors want proof that 2026 is a floor, not a peak. The next catalysts are concrete: China's soybean purchases, the fourth-quarter 45Z true-up, 2027 crush contracting, and the first precision-fermentation milestones. Until those arrive, ADM is a cash-generating commodity processor with a policy tailwind and a growth story that is still mostly in the lab. The market is waiting for the fourth raise — or at least for the first one that is not driven by a policy mark-up.